The Effect of N-acetylcysteine on hsCRP in Patients on Continues Ambulatory Peritoneal Dialysis; A Quasi-Experimental Study

AUTHORS

Farzaneh Najafi 1 , Razieh Sadat Mousavi-Roknabadi ORCID 2 , 3 , * , Azar Pirdehghan 4 , 5 , Masoud Rahimian 6 , Nader Nourimajalan 6

1 Department of Internal Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

2 Emergency Medicine Department, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran

3 Student Research Committee, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

4 Department of Community Medicine, School of Medicine, Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamedan, IR Iran

5 Department of Community Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

6 Department of Internal Medicine, School of Medicine, Shahid Sadoughi General Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, IR Iran

How to Cite: Najafi F, Mousavi-Roknabadi R S, Pirdehghan A, Rahimian M, Nourimajalan N. The Effect of N-acetylcysteine on hsCRP in Patients on Continues Ambulatory Peritoneal Dialysis; A Quasi-Experimental Study, Nephro-Urol Mon.2021 In Press(In Press): e113990.

ARTICLE INFORMATION

Nephro-Urology Monthly: In Press (In Press); e113990
Published Online: May 25, 2021
Article Type: Research Article
Received: February 22, 2021
Accepted: March 03, 2021
Accepted Article scheduled for 13 (2)
READ FULL TEXT

Abstract

Background: Inflammatory process is proved in patients with chronic kidney disease (CKD), which is one of the most cause of mortality and morbidity in these patients. N-acetylcysteine (NAC) is known as an anti-oxidant drug with anti-inflammatory effects.

Objective: This study aimed was to evaluate the effects of NAC on hsCRP level in CKD patients on peritoneal dialysis.

Methods: This quasi-experimental self-controlled study was conducted on adult CKD patients on peritoneal dialysis, who were referred to peritoneal dialysis clinic. The participants were divided into 2 groups (A: CRP of 5-15mg/L and B: CRP<5mg/L), and both groups were treated with oral NAC 600mg, 2 times/day for 8 weeks. The hsCRP were measured before and after the intervention. Then, all collected data were analyzed.

Results: Forty patients were enrolled (24 as group A and 26 as group B). NAC could reduce the hsCRP level in both groups (P=0.001 in group A vs. P=0.002 in group B), but this reduction was more in group A (P=0.013). The hsCRP reduction was more in women generally (P=0.002), and women in group B (P=0.02). The hsCRP difference had a significant relationship with underlying disease (P=0.009). There was no significant correlation between hsCRP difference and age (r=-0.173, P=0.285), as well as duration of dialysis.

Conclusion: Administration of NAC (600mg, 2 times/day for 8 weeks) reduce the level of hsCRP in patients on peritoneal dialysis, significantly, especially in CRP of 5-15mh/L. This reduction has no relationship with age and duration of dialysis, but was more in women.

Fulltext

© 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: